Company / R&D Expense
Savara Inc R&D Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$78.0M
FY2024
5-year range
$27.9M / $78.0M
FY2020-FY2024
Trend
+76.3%
vs FY2023
Sector context
#159 of 210
Health Care
What the data says
Savara Inc's r&d expense of $78M is lower than 76% of companies in the Health Care sector (FY2024). Improved from $28M to $78M over the past 2 years.
Based on SEC 10-K filings.
$78M in FY2024 with a 5-year CAGR of +16.0%.
Improved from $28M to $78M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +39.1%
- 5-Year CAGR
- +16.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 210This company $78.0M Sector average $644.1M
▼
-87.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +16.0%, indicating consistent growth.
- In FY2024, r&d expense increased 76.3% year-over-year.
- Ranks #159 out of 210 companies in the Health Care sector.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $78.0M | +76.3% |
| FY2023 | $44.3M | +58.8% |
| FY2022 | $27.9M | -3.8% |
| FY2021 | $29.0M | -17.3% |
| FY2020 | $35.0M | -5.7% |
| FY2019 | $37.2M | +0.0% |
| FY2018 | $37.2M | +100.8% |
| FY2017 | $18.5M | +126.3% |
| FY2016 | $8.2M | +89.4% |
| FY2015 | $4.3M | -77.8% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026